Roivant Sciences Ltd - Asset Resilience Ratio
Roivant Sciences Ltd (ROIV) has an Asset Resilience Ratio of 58.40% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ROIV working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Roivant Sciences Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Roivant Sciences Ltd (ROIV) total assets.
Liquid Assets Composition Over Time
This chart breaks down Roivant Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Roivant Sciences Ltd (ROIV) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.05 Billion | 58.4% |
| Total Liquid Assets | $3.05 Billion | 58.40% |
Asset Resilience Insights
- Very High Liquidity: Roivant Sciences Ltd maintains exceptional liquid asset reserves at 58.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Roivant Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Roivant Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Roivant Sciences Ltd (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Roivant Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 39.94% | $2.17 Billion | $5.44 Billion | +39.87pp |
| 2024-03-31 | 0.07% | $5.37 Million | $7.22 Billion | -0.14pp |
| 2023-03-31 | 0.21% | $5.01 Million | $2.39 Billion | -0.32pp |
| 2022-03-31 | 0.53% | $13.63 Million | $2.59 Billion | -2.36pp |
| 2021-03-31 | 2.89% | $77.70 Million | $2.69 Billion | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more